At 26 weeks , 36.6 % of the combination therapy group achieved prolonged and 38.2 % achieved 7-day point-prevalence smoking abstinence compared with 27.6 % and 31.9 % in varenicline monotherapy ( OR , 1.52 ; 95 % CI , 1.04-2 .22 ; P = .03 and OR , 1.32 ; 95 % CI , 0.91-1 .91 ; P = .14 , respectively ) .